Patient Portal

David Michael Holtzman, MD

Andrew B. and Gretchen P. Jones Professor of Neurology
Charlotte and Paul Hagemann Professor of Neurology
Chairman, Department of Neurology
Professor, Molecular Biology and Pharmacology
Neurologist-in-Chief, Barnes-Jewish Hospital

Specialty Areas

Neurology - Adult
Memory Disorders and Diagnosis
Alzheimer's Disease
Dementia

Board Certifications

Neurology

Hospital Affiliations

Barnes-Jewish Hospital

Areas of Clinical Interest

Neurology, molecular biology, pharmacology, nervous system, Alzheimer's disease, memory, brain research, cerebral blood flow, metabolism, neuroscience, lipid research, neuron, mental retardation, Down's syndrome, neonatal hypoxic-ischemia, brain disorders, spinal fluid.

  • Maps & Directions
  • Education
  • Publication & Research
  • Financial Disclosures

Maps & Directions

Maps & Directions

Center for Advanced Medicine
Memory Diagnostic Center

4921 Parkview Place
St. Louis, MO 63110

Suite: C
Floor: 6
Office Phone: (314) 286-1967
Fax: (314) 286-1985
Email: holtzman@neuro.wustl.edu

Education

Education

Residency: Neurology, University of California, San Francisco, California 1989
Medical Degree: Northwestern University, Chicago, Illinois 1985
BS: Science in Medical Education, Northwestern University, Chicago, Illinois 1983

Publication & Research

Publication & Research

Emerging cerebrospinal fluid biomarkers in autosomal dominant Alzheimer's disease.
Schindler SE, Li Y, Todd KW, Herries EM, Henson RL, Gray JD, Wang G, Graham DL, Shaw LM, Trojanowski JQ, Hassenstab JJ, Benzinger TLS, Cruchaga C, Jucker M, Levin J, Chhatwal JP, Noble JM, Ringman JM, Graff-Radford NR, Holtzman DM, Ladenson JH, Morris JC, Bateman RJ, Xiong C, Fagan AM, Dominantly Inherited Alzheimer Network.
Alzheimers Dement. 2019 Mar 4; pii: S1552-5260(19)30013-5. doi: 10.1016/j.jalz.2018.12.019.

PMID:
    30846386
    [PubMed - as supplied by publisher]
Related citations


Dural lymphatics regulate clearance of extracellular tau from the CNS.
Patel TK, Habimana-Griffin L, Gao X, Xu B, Achilefu S, Alitalo K, McKee CA, Sheehan PW, Musiek ES, Xiong C, Coble D, Holtzman DM
Mol Neurodegener. 2019 Feb 27; 14(1)11. doi: 10.1186/s13024-019-0312-x.

PMID:
    30813965
    [PubMed - in process]
Related citations


Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers.
Gordon BA, Blazey TM, Christensen J, Dincer A, Flores S, Keefe S, Chen C, Su Y, McDade EM, Wang G, Li Y, Hassenstab J, Aschenbrenner A, Hornbeck R, Jack CR Jr, Ances BM, Berman SB, Brosch JR, Galasko D, Gauthier S, Lah JJ, Masellis M, van Dyck CH, Mintun MA, Klein G, Ristic S, Cairns NJ, Marcus DS, Xiong C, Holtzman DM, Raichle ME, Morris JC, Bateman RJ, Benzinger TLS
Brain. 2019 Feb 11; doi: 10.1093/brain/awz019.

PMID:
    30753379
    [PubMed - as supplied by publisher]
Related citations


Dr. Jekyll and Mr. Hyde: ApoE explains opposing effects of neuronal LRP1.
Strickland MR, Holtzman DM
J Clin Invest. 2019 Mar 1; 129(3)969-971. doi: 10.1172/JCI127578.

PMID:
    30741722
    [PubMed - in process]
Related citations


Multi-Modal Home Sleep Monitoring in Older Adults.
Toedebusch CD, McLeland JS, Schaibley CM, Banks IR, Boyd J, Morris JC, Holtzman DM, Lucey BP
J Vis Exp. 2019 Jan 26; (143)doi: 10.3791/58823.

PMID:
    30741255
    [PubMed - in process]
Related citations


Reply to "obstructive sleep apnea treatment and amyloid-β in cerebrospinal fluid".
Ju YS, Holtzman DM
Ann Neurol. 2019 Mar; 85(3)460-461. doi: 10.1002/ana.25424.

PMID:
    30706528
    [PubMed - in process]
Related citations


The sleep-wake cycle regulates brain interstitial fluid tau in mice and CSF tau in humans.
Holth JK, Fritschi SK, Wang C, Pedersen NP, Cirrito JR, Mahan TE, Finn MB, Manis M, Geerling JC, Fuller PM, Lucey BP, Holtzman DM
Science. 2019 Feb 22; 363(6429)880-884. doi: 10.1126/science.aav2546.

PMID:
    30679382
    [PubMed - in process]
Related citations


"Alzheimer's disease" is neither "Alzheimer's clinical syndrome" nor "dementia".
Jagust W, Jack CR Jr, Bennett DA, Blennow K, Haeberlein SB, Holtzman DM, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Sperling R
Alzheimers Dement. 2019 Jan; 15(1)153-157. doi: 10.1016/j.jalz.2018.11.002.

PMID:
    30642435
    [PubMed - in process]
Related citations


Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease.
Lucey BP, McCullough A, Landsness EC, Toedebusch CD, McLeland JS, Zaza AM, Fagan AM, McCue L, Xiong C, Morris JC, Benzinger TLS, Holtzman DM
Sci Transl Med. 2019 Jan 9; 11(474)pii: eaau6550. doi: 10.1126/scitranslmed.aau6550.

PMID:
    30626715
    [PubMed - in process]
Related citations


Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE.
Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, Nuscher B, Xiong M, Ghasemigharagoz A, Katzmarski N, Krasemann S, Lichtenthaler SF, Müller SA, Colombo A, Monasor LS, Tahirovic S, Herms J, Willem M, Pettkus N, Butovsky O, Bartenstein P, Edbauer D, Rominger A, Ertürk A, Grathwohl SA, Neher JJ, Holtzman DM, Meyer-Luehmann M, Haass C
Nat Neurosci. 2019 Feb; 22(2)191-204. doi: 10.1038/s41593-018-0296-9.

PMID:
    30617257
    [PubMed - in process]
Related citations


Assessment of Racial Disparities in Biomarkers for Alzheimer Disease.
Morris JC, Schindler SE, McCue LM, Moulder KL, Benzinger TLS, Cruchaga C, Fagan AM, Grant E, Gordon BA, Holtzman DM, Xiong C
JAMA Neurol. 2019 Jan 7; doi: 10.1001/jamaneurol.2018.4249.

PMID:
    30615028
    [PubMed - as supplied by publisher]
Related citations


Obstructive sleep apnea treatment, slow wave activity, and amyloid-β.
Ju YS, Zangrilli MA, Finn MB, Fagan AM, Holtzman DM
Ann Neurol. 2019 Feb; 85(2)291-295. doi: 10.1002/ana.25408.

PMID:
    30597615
    [PubMed - in process]
Related citations


New insights into the role of TREM2 in Alzheimer's disease.
Gratuze M, Leyns CEG, Holtzman DM
Mol Neurodegener. 2018 Dec 20; 13(1)66. doi: 10.1186/s13024-018-0298-9.

PMID:
    30572908
    [PubMed - in process]
Related citations


Amyloid-β 'seeds' in old vials of growth hormone.
Huynh TV, Holtzman DM
Nature. 2018 Dec; 564(7736)354-355. doi: 10.1038/d41586-018-07604-6.

PMID:
    30546137
    [PubMed - in process]
Related citations


Depression and Alzheimer's Disease Biomarkers Predict Driving Decline.
Babulal GM, Chen S, Williams MM, Trani JF, Bakhshi P, Chao GL, Stout SH, Fagan AM, Benzinger TLS, Holtzman DM, Morris JC, Roe CM
J Alzheimers Dis. 2018; 66(3)1213-1221. doi: 10.3233/JAD-180564.

PMID:
    30400098
    [PubMed - in process]
Related citations


High-affinity interactions and signal transduction between Aβ oligomers and TREM2.
Lessard CB, Malnik SL, Zhou Y, Ladd TB, Cruz PE, Ran Y, Mahan TE, Chakrabaty P, Holtzman DM, Ulrich JD, Colonna M, Golde TE
EMBO Mol Med. 2018 Nov; 10(11)pii: e9027. doi: 10.15252/emmm.201809027.

PMID:
    30341064
    [PubMed - in process]
Related citations


Blood-brain barrier-associated pericytes internalize and clear aggregated amyloid-β42 by LRP1-dependent apolipoprotein E isoform-specific mechanism.
Ma Q, Zhao Z, Sagare AP, Wu Y, Wang M, Owens NC, Verghese PB, Herz J, Holtzman DM, Zlokovic BV
Mol Neurodegener. 2018 Oct 19; 13(1)57. doi: 10.1186/s13024-018-0286-0.

PMID:
    30340601
    [PubMed - indexed for MEDLINE]
Related citations


Incident cognitive impairment: longitudinal changes in molecular, structural and cognitive biomarkers.
Roe CM, Ances BM, Head D, Babulal GM, Stout SH, Grant EA, Hassenstab J, Xiong C, Holtzman DM, Benzinger TLS, Schindler SE, Fagan AM, Morris JC
Brain. 2018 Nov 1; 141(11)3233-3248. doi: 10.1093/brain/awy244.

PMID:
    30304397
    [PubMed - in process]
Related citations


Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease.
McDade E, Wang G, Gordon BA, Hassenstab J, Benzinger TLS, Buckles V, Fagan AM, Holtzman DM, Cairns NJ, Goate AM, Marcus DS, Morris JC, Paumier K, Xiong C, Allegri R, Berman SB, Klunk W, Noble J, Ringman J, Ghetti B, Farlow M, Sperling RA, Chhatwal J, Salloway S, Graff-Radford NR, Schofield PR, Masters C, Rossor MN, Fox NC, Levin J, Jucker M, Bateman RJ, Dominantly Inherited Alzheimer Network.
Neurology. 2018 Oct 2; 91(14)e1295-e1306. doi: 10.1212/WNL.0000000000006277.

PMID:
    30217935
    [PubMed - in process]
Related citations


Interplay between innate immunity and Alzheimer disease: APOE and TREM2 in the spotlight.
Shi Y, Holtzman DM
Nat Rev Immunol. 2018 Dec; 18(12)759-772. doi: 10.1038/s41577-018-0051-1.

PMID:
    30140051
    [PubMed - in process]
Related citations

Financial Disclosures

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.

This physician reported the following financial interests during calendar year 2017:

Company Name: C2N Diagnostics

Royalties: > $250,000

Equity: Yes

Consulting/Advisory Board: $20,000 - $39,999

Speaker Fees:

Reporting Date: May 01, 2018


Company Name: Denali

Royalties: $1 - $9,999

Equity: No

Consulting/Advisory Board: $10,000 - $19,999

Speaker Fees:

Reporting Date: May 01, 2018

Areas of Research Interest

Underlying mechanisms that lead to Alzheimer's disease.